ACADIA Pharmaceuticals Inc. Common Stock (ACAD)

FairStock Score: 77/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

ACADIA is a small biopharma selling two approved medicines, NUPLAZID and DAYBUE, for neurological and rare disease. That gives it real revenue, not just a pipeline dream: FY2025 revenue was $1.1B with net income $391.0M and diluted EPS $2.30, up from FY2024 revenue $957.8M, net income $226.5M, EPS $1.36, and a FY2023 loss of $61.3M. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, had revenue $308.0M, net income $31.5M, and diluted EPS $0.18, versus fiscal Q2 2025 revenue $264.6M, net income $26.7M, EPS $0.16. So the direction is good, but quarterly profits swing: fiscal Q1 2026 net income was only $3.6M, while fiscal Q3 2025 was $71.8M. The balance sheet is conservative with debt-to-equity 0.06, and FairStock's ROE is 35.74%, though ROCE is only 3.64%, so returns on total capital are not as impressive as equity returns. Free cash flow TTM is $145.6M, a 4.5% FCF yield. At the 2026-10-13 close of $18.62, FairStock shows P/E 8.35, P/B 2.45, PEG 0.46, EV/EBITDA 29.45, Graham Number $19.51, and margin of safety 4.56%. That is not demanding on earnings but not a bargain on cash flow. The moat looks narrow and concentrated in two products; competition remains a risk. The Lynch category is TURNAROUND—returned to profit after a loss within the last three years. I want steadier cash generation before calling it a high-quality compounder.

In plain English: ACADIA makes medicines for brain and rare diseases, including NUPLAZID and DAYBUE. The business has become profitable after losses, sales and profits are growing, and it has little debt. At the recent price, the shares look around fair to slightly cheap compared with current earnings, but profits have been uneven and the company depends on a small number of products.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer